Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research report report published on Saturday, December 30th.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
Other equities analysts have also issued reports about the stock. ValuEngine lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Thursday, November 2nd. Jefferies Group lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a hold rating to a buy rating in a report on Thursday, December 21st. Finally, Canaccord Genuity restated a buy rating and issued a $22.00 price objective on shares of OraSure Technologies in a report on Tuesday, September 19th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $19.65.
Shares of OraSure Technologies (OSUR) traded down $0.03 during midday trading on Friday, reaching $19.39. 268,227 shares of the company were exchanged, compared to its average volume of 655,814. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01. The stock has a market cap of $1,170.00, a price-to-earnings ratio of 37.29, a P/E/G ratio of 4.58 and a beta of 1.27.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. During the same period in the previous year, the business earned $0.11 EPS. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. equities research analysts anticipate that OraSure Technologies will post 0.43 EPS for the current year.
In related news, Director Mara G. Aspinall bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was acquired at an average price of $14.23 per share, with a total value of $71,150.00. Following the transaction, the director now owns 5,000 shares in the company, valued at approximately $71,150. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.40% of the company’s stock.
Large investors have recently bought and sold shares of the business. State Street Corp grew its position in OraSure Technologies by 6.9% in the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after purchasing an additional 106,326 shares during the period. USA Financial Portformulas Corp grew its position in OraSure Technologies by 31.0% in the 2nd quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after purchasing an additional 13,421 shares during the period. Chicago Equity Partners LLC grew its position in OraSure Technologies by 38.3% in the 2nd quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock worth $1,354,000 after purchasing an additional 21,730 shares during the period. 361 Capital LLC grew its position in OraSure Technologies by 59.9% in the 2nd quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 10,107 shares during the period. Finally, Macquarie Group Ltd. bought a new stake in shares of OraSure Technologies during the 2nd quarter valued at $892,000. 94.43% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/10/zacks-investment-research-upgrades-orasure-technologies-osur-to-hold-2.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Get a free copy of the Zacks research report on OraSure Technologies (OSUR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.